Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




First TB Molecular Diagnostic Test Granted WHO Prequalification

By LabMedica International staff writers
Posted on 09 Dec 2024

Tuberculosis (TB) is one of the most deadly infectious diseases globally, responsible for over a million deaths each year and imposing significant socioeconomic challenges, particularly in low- and middle-income countries. More...

The early and accurate detection of TB, particularly drug-resistant strains, remains a critical and difficult global health concern. Now, a new diagnostic test for TB and antibiotic susceptibility has become the first to meet the World Health Organization's (WHO) prequalification standards, improving access to timely diagnosis and treatment.

Cepheid’s (Sunnyvale, CA, USA) molecular diagnostic test for TB called Xpert MTB/RIF Ultra has been granted prequalification by the WHO, making it the first test for TB diagnosis and antibiotic susceptibility testing to meet WHO's prequalification standards. The test, designed for use on the GeneXpert Instrument System, is a nucleic acid amplification test (NAAT) that detects the genetic material of Mycobacterium tuberculosis, the bacterium responsible for TB, from sputum samples and delivers results in just hours. Additionally, the test identifies mutations associated with rifampicin resistance, which is a key marker of multidrug-resistant TB. It is specifically intended for patients who screen positive for pulmonary TB and have either not started anti-tuberculosis treatment or have received less than three days of therapy in the past six months.

The WHO prequalification of this test is expected to guarantee the quality of diagnostic tools, helping to enhance early diagnosis and treatment accessibility. It supports the WHO’s endorsement approach, which is based on emerging evidence, diagnostic accuracy, patient outcomes, and the emphasis on accessibility and equity, with prequalification focusing on quality, safety, and performance. WHO’s prequalification process for this test was based on data provided by Cepheid and a review by Singapore’s Health Sciences Authority (HSA), the product’s regulatory body.

“This first prequalification of a diagnostic test for tuberculosis marks a critical milestone in WHO’s efforts to support countries in scaling up and accelerating access to high-quality TB assays that meet both WHO recommendations and its stringent quality, safety, and performance standards,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “It underscores the importance of such groundbreaking diagnostic tools in addressing one of the world's deadliest infectious diseases.”

“High-quality diagnostic tests are the cornerstone of effective TB care and prevention,” added Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification. “Prequalification paves the way for equitable access to cutting-edge technologies, empowering countries to address the dual burden of TB and drug-resistant TB.”

Related Links:
Cepheid


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.